Literature DB >> 28889092

Quantitative MR spectroscopic imaging in metachromatic leukodystrophy: value for prognosis and treatment.

Diane F van Rappard1,2, Antoine Klauser3, Marjan E Steenweg1,2, Jaap Jan Boelens4, Marianna Bugiani1,2,5, Marjo S van der Knaap1,2, Nicole I Wolf1,2, Petra J W Pouwels2,6.   

Abstract

OBJECTIVE: To determine whether proton magnetic resonance spectroscopic imaging is useful in predicting clinical course of patients with metachromatic leukodystrophy (MLD), an inherited white matter disorder treatable with haematopoietic cell transplantation (HCT).
METHODS: 21 patients with juvenile or adult MLD (12 HCT-treated) were compared with 16 controls in the same age range. Clinical outcome was determined as good, moderate or poor. Metabolites were quantified in white matter, and significance of metabolite concentrations at baseline for outcome prediction was assessed using logistic regression analysis. Evolution of metabolic changes was assessed for patients with follow-up examinations.
RESULTS: In this retrospective study, 16 patients with baseline scans were included, 5 with good, 3 with moderate and 8 with poor outcome, and 16 controls. We observed significant group differences for all metabolite concentrations in white matter (p<0.001). Compared with controls, patients had decreased N-acetylaspartate and glutamate, and increased myo-inositol and lactate, most pronounced in patients with poor outcome (post hoc, all p<0.05). Logistic regression showed complete separation of data. Creatine could distinguish poor from moderate and good outcome, the sum of glutamate and glutamine could distinguish good from moderate and poor outcome, and N-acetylaspartate could distinguish all outcome groups. For 13 patients (8 with baseline scans), one or more follow-up examinations were evaluated, revealing stabilisation or even partial normalisation of metabolites in patients with moderate and good outcome, clearly visible in the ratio of choline/N-acetylaspartate.
CONCLUSION: In MLD, quantitative spectroscopic imaging at baseline is predictive for outcome and aids in determining eligibility for HCT. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28889092     DOI: 10.1136/jnnp-2017-316364

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  6 in total

Review 1.  Clinical 1H MRS in childhood neurometabolic diseases - part 2: MRS signatures.

Authors:  Matthew T Whitehead; Lillian M Lai; Stefan Blüml
Journal:  Neuroradiology       Date:  2022-02-28       Impact factor: 2.804

2.  Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi).

Authors:  Daphne H Schoenmakers; Shanice Beerepoot; Sibren van den Berg; Laura Adang; Annette Bley; Jaap-Jan Boelens; Francesca Fumagalli; Wim G Goettsch; Sabine Grønborg; Samuel Groeschel; Peter M van Hasselt; Carla E M Hollak; Caroline Lindemans; Fanny Mochel; Peter G M Mol; Caroline Sevin; Ayelet Zerem; Ludger Schöls; Nicole I Wolf
Journal:  Orphanet J Rare Dis       Date:  2022-02-14       Impact factor: 4.123

3.  Identification of neurodegeneration indicators and disease progression in metachromatic leukodystrophy using quantitative NMR-based urinary metabolomics.

Authors:  Lucia Laugwitz; Laimdota Zizmare; Vidiyaah Santhanakumaran; Claire Cannet; Judith Böhringer; Jürgen G Okun; Manfred Spraul; Ingeborg Krägeloh-Mann; Samuel Groeschel; Christoph Trautwein
Journal:  JIMD Rep       Date:  2022-01-27

4.  Diffusion tensor imaging in metachromatic leukodystrophy.

Authors:  Diane F van Rappard; Marsh Königs; Marjan E Steenweg; Jaap Jan Boelens; Jaap Oosterlaan; Marjo S van der Knaap; Nicole I Wolf; Petra J W Pouwels
Journal:  J Neurol       Date:  2018-01-30       Impact factor: 4.849

Review 5.  Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches.

Authors:  Alisa A Shaimardanova; Daria S Chulpanova; Valeriya V Solovyeva; Aysilu I Mullagulova; Kristina V Kitaeva; Cinzia Allegrucci; Albert A Rizvanov
Journal:  Front Med (Lausanne)       Date:  2020-10-20

6.  T2-Pseudonormalization and Microstructural Characterization in Advanced Stages of Late-infantile Metachromatic Leukodystrophy.

Authors:  Pascal Martin; Gisela E Hagberg; Thomas Schultz; Klaus Harzer; Uwe Klose; Benjamin Bender; Thomas Nägele; Klaus Scheffler; Ingeborg Krägeloh-Mann; Samuel Groeschel
Journal:  Clin Neuroradiol       Date:  2020-11-23       Impact factor: 3.649

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.